American Century Companies Inc. Sells 236,002 Shares of Vaxcyte, Inc. $PCVX

American Century Companies Inc. lowered its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 40.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 351,052 shares of the company’s stock after selling 236,002 shares during the quarter. American Century Companies Inc. owned 0.27% of Vaxcyte worth $11,413,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Cetera Investment Advisers grew its position in Vaxcyte by 32.7% in the first quarter. Cetera Investment Advisers now owns 6,749 shares of the company’s stock worth $255,000 after acquiring an additional 1,665 shares in the last quarter. XTX Topco Ltd lifted its stake in shares of Vaxcyte by 355.9% in the 1st quarter. XTX Topco Ltd now owns 13,796 shares of the company’s stock valued at $521,000 after purchasing an additional 10,770 shares during the last quarter. US Bancorp DE boosted its holdings in shares of Vaxcyte by 7.2% in the 1st quarter. US Bancorp DE now owns 5,344 shares of the company’s stock worth $202,000 after purchasing an additional 357 shares during the period. PNC Financial Services Group Inc. increased its position in shares of Vaxcyte by 5.8% during the 1st quarter. PNC Financial Services Group Inc. now owns 9,600 shares of the company’s stock valued at $362,000 after purchasing an additional 524 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in shares of Vaxcyte by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 12,043,805 shares of the company’s stock valued at $454,774,000 after purchasing an additional 82,118 shares during the last quarter. 96.78% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. Leerink Partners set a $77.00 target price on shares of Vaxcyte and gave the stock an “outperform” rating in a report on Wednesday, November 19th. Cowen reaffirmed a “buy” rating on shares of Vaxcyte in a research report on Thursday, August 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vaxcyte in a research report on Tuesday, October 14th. The Goldman Sachs Group initiated coverage on shares of Vaxcyte in a research report on Friday, September 12th. They issued a “neutral” rating and a $38.00 price objective for the company. Finally, BTIG Research restated a “buy” rating and issued a $85.00 target price on shares of Vaxcyte in a research note on Monday, November 10th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $97.83.

Vaxcyte Stock Performance

NASDAQ PCVX opened at $46.07 on Friday. The firm’s 50 day moving average price is $43.94 and its 200-day moving average price is $36.99. Vaxcyte, Inc. has a 52-week low of $27.66 and a 52-week high of $94.60. The company has a market cap of $6.03 billion, a PE ratio of -9.52 and a beta of 1.28.

Vaxcyte (NASDAQ:PCVX) last posted its earnings results on Tuesday, November 4th. The company reported ($1.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.29). During the same period in the prior year, the firm posted ($0.83) earnings per share. On average, analysts forecast that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.